Latest news

Orchard Therapeutics announces presentations from UCL/GOSH and UCLA academic collaborators on clinical data in ADA-SCID using ex-vivo lentiviral gene therapy at September 2016 ESID and ESGCT congresses

Orchard Therapeutics Limited is proud to report that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Monday September 19 in Boston, MA.